Co-crystal of tramadol–celecoxib (CTC) for acute moderate-to-severe pain

Abstract

Results from phase 3 trials suggest that the modified physicochemical properties of tramadol and celecoxib in CTC translate into an improved clinical benefit-risk profile, including fewer opioid-related adverse effects due to lower overall opioid dosing.